Telix Pharmaceuticals revenue rises 19% to US$245M

Full story: https://grafa.com/en/news/australia/telix-pharmaceuticals-revenue-rises-19-to-us-245m

Telix Pharmaceuticals reported group revenue of US$245 million for the third quarter of 2026, marking a 19% increase from the prior corresponding period.

Strong commercial demand for precision medicine imaging products drove quarterly revenue higher.
The company reaffirmed its full-year 2026 revenue guidance to exceed US$1 billion.

Telix Pharmaceuticals (ASX:TLX) generated US$245 million in group revenue during the third quarter of 2026, up 19% in the prior-year period.

The quarterly revenue growth was primarily led by a 30% increase in precision medicine revenue to US$201 million, which offset a 6% decline in manufacturing solutions revenue.

The company stated that the transaction with Isotope Technologies Munich SE is expected to position the platform with one of the industry's broadest therapeutics pipelines.

In addition, research and development expenditure guidance for the full 2026 year was revised to a range of US$240 million to US$260 million.

Following the announcement, the Telix Pharmaceuticals share price was unchanged at $15.76.

The company secured regulatory approval from the U.S. Food and Drug Administration for its Pixclara glioma imaging agent in September.

Telix Pharmaceuticals also completed patient enrolment for its Phase 3 pre-biopsy prostate cancer study while securing fast track designation.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":620713954844752,"tweetId":"620713954844752","gmtCreate":1792572198042,"gmtModify":1792572205387,"author":{"id":4169784042383112,"idStr":"4169784042383112","authorId":4169784042383112,"authorIdStr":"4169784042383112","name":"Grafa","avatar":"https://community-static.tradeup.com/news/ec1614006170d0aa3182195a94e8944d","vip":2,"userType":2,"introduction":"Grafa generates AI-driven data, news and analysis about NYSE, Nasdaq and ASX stocks","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":258,"starInvestorFlag":false},"themes":[],"images":[{"img":"https://community-static.tradeup.com/news/c483f3eaa8257ec11b361bd80c66a0d7","width":"1456","height":"816"}],"coverImages":[{"img":"https://community-static.tradeup.com/news/c483f3eaa8257ec11b361bd80c66a0d7","width":"1456","height":"816"}],"title":"Telix Pharmaceuticals revenue rises 19% to US$245M","html":"<html><head></head><body><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/c483f3eaa8257ec11b361bd80c66a0d7\" tg-width=\"1456\" tg-height=\"816\"></p>\n<p>Full story: https://grafa.com/en/news/australia/telix-pharmaceuticals-revenue-rises-19-to-us-245m</p>\n<p>Telix Pharmaceuticals reported group revenue of US$245 million for the third quarter of 2026, marking a 19% increase from the prior corresponding period.</p>\n<ul>\n <li>\n  <p>Strong commercial demand for precision medicine imaging products drove quarterly revenue higher.</p></li>\n <li>\n  <p>The company reaffirmed its full-year 2026 revenue guidance to exceed US$1 billion.</p></li>\n</ul>\n<p style=\"text-align: start;\">Telix Pharmaceuticals (ASX:TLX) generated US$245 million in group revenue during the third quarter of 2026, up 19% in the prior-year period.</p>\n<p style=\"text-align: start;\">The quarterly revenue growth was primarily led by a 30% increase in precision medicine revenue to US$201 million, which offset a 6% decline in manufacturing solutions revenue.</p>\n<p style=\"text-align: start;\">The company stated that the transaction with Isotope Technologies Munich SE is expected to position the platform with one of the industry's broadest therapeutics pipelines.</p>\n<p style=\"text-align: start;\">In addition, research and development expenditure guidance for the full 2026 year was revised to a range of US$240 million to US$260 million.</p>\n<p style=\"text-align: start;\">Following the announcement, the Telix Pharmaceuticals share price was unchanged at $15.76.</p>\n<p style=\"text-align: start;\">The company secured regulatory approval from the U.S. Food and Drug Administration for its Pixclara glioma imaging agent in September.</p>\n<p style=\"text-align: start;\">Telix Pharmaceuticals also completed patient enrolment for its Phase 3 pre-biopsy prostate cancer study while securing fast track designation.</p></body></html>","htmlText":"<html><head></head><body><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/c483f3eaa8257ec11b361bd80c66a0d7\" tg-width=\"1456\" tg-height=\"816\"></p>\n<p>Full story: https://grafa.com/en/news/australia/telix-pharmaceuticals-revenue-rises-19-to-us-245m</p>\n<p>Telix Pharmaceuticals reported group revenue of US$245 million for the third quarter of 2026, marking a 19% increase from the prior corresponding period.</p>\n<ul>\n <li>\n  <p>Strong commercial demand for precision medicine imaging products drove quarterly revenue higher.</p></li>\n <li>\n  <p>The company reaffirmed its full-year 2026 revenue guidance to exceed US$1 billion.</p></li>\n</ul>\n<p style=\"text-align: start;\">Telix Pharmaceuticals (ASX:TLX) generated US$245 million in group revenue during the third quarter of 2026, up 19% in the prior-year period.</p>\n<p style=\"text-align: start;\">The quarterly revenue growth was primarily led by a 30% increase in precision medicine revenue to US$201 million, which offset a 6% decline in manufacturing solutions revenue.</p>\n<p style=\"text-align: start;\">The company stated that the transaction with Isotope Technologies Munich SE is expected to position the platform with one of the industry's broadest therapeutics pipelines.</p>\n<p style=\"text-align: start;\">In addition, research and development expenditure guidance for the full 2026 year was revised to a range of US$240 million to US$260 million.</p>\n<p style=\"text-align: start;\">Following the announcement, the Telix Pharmaceuticals share price was unchanged at $15.76.</p>\n<p style=\"text-align: start;\">The company secured regulatory approval from the U.S. Food and Drug Administration for its Pixclara glioma imaging agent in September.</p>\n<p style=\"text-align: start;\">Telix Pharmaceuticals also completed patient enrolment for its Phase 3 pre-biopsy prostate cancer study while securing fast track designation.</p></body></html>","text":"Full story: https://grafa.com/en/news/australia/telix-pharmaceuticals-revenue-rises-19-to-us-245m Telix Pharmaceuticals reported group revenue of US$245 million for the third quarter of 2026, marking a 19% increase from the prior corresponding period. Strong commercial demand for precision medicine imaging products drove quarterly revenue higher. The company reaffirmed its full-year 2026 revenue guidance to exceed US$1 billion. Telix Pharmaceuticals (ASX:TLX) generated US$245 million in group revenue during the third quarter of 2026, up 19% in the prior-year period. The quarterly revenue growth was primarily led by a 30% increase in precision medicine revenue to US$201 million, which offset a 6% decline in manufacturing solutions revenue. The company stated that the transaction with Isotope Technologies Munich SE is expected to position the platform with one of the industry's broadest therapeutics pipelines. In addition, research and development expenditure guidance for the full 2026 year was revised to a range of US$240 million to US$260 million. Following the announcement, the Telix Pharmaceuticals share price was unchanged at $15.76. The company secured regulatory approval from the U.S. Food and Drug Administration for its Pixclara glioma imaging agent in September. Telix Pharmaceuticals also completed patient enrolment for its Phase 3 pre-biopsy prostate cancer study while securing fast track designation.","highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/620713954844752","repostId":0,"isVote":1,"tweetType":1,"viewCount":1,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":1236,"optionInvolvedFlag":false,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/620713954844752"}